King Pharma's Second Quarter Disappoints; Looks to Pain Approvals and Diversification
This article was originally published in The Pink Sheet Daily
Executive Summary
With the Skelaxin story "over," King is pushing ahead with plans to resubmit abuse-deterrent opioids Remoxy and Acurox for FDA approval and fine-tuning its sales force to improve performance of Embeda.